E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with high-output ileostomy or jejunostomy and failure of treatment with loperamide +/- codein syrup
|
|
E.1.1.1 | Medical condition in easily understood language |
Following digestive surgery during which an enterostomy was created , the stomy gives high-output not controlled with usual medical treatment (loperamide +/- codeine). |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021321 |
E.1.2 | Term | Ileostomy |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10023180 |
E.1.2 | Term | Jejunostomy |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare the efficacy of pasireotide versus placebo in reduction of high-output (>1000 ml/24h) enterostomy in patients refractory to usual medical treatment |
|
E.2.2 | Secondary objectives of the trial |
- Estimate the success rate of pasireotide and placebo. - Compare the decrease in the length of hospitalization with pasireotide versus placebo. - Compare the incidence of prematured closure of stoma due to high-output with pasireotide versus placebo. - Evaluate the economic impact of pasireotide in this indication. - Evaluate the safety of pasireotide in this indication.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male and Female patients ≥ 18 years old ; - Patients with high-output ileostomy or jejunostomy > 1000 ml/24h ; - Patients with failure of treatment with loperamide (up to 8 capsules/24h) +/- codein syrup (10 mg x 3/24h) during 5 days ; - Patients who gave its written informed consent to participate to the study ; - Patients affiliated to a social insurance regime.
|
|
E.4 | Principal exclusion criteria |
- Male and Female patients < 18 years old ; - Patients who did not give its written informed consent to participate to the study ; - Patients who received somatostatin analogues during the month before inclusion ; - Patients with symptomatic cholelithiasis or acute or chronic pancreatitis ; - Patients with uncontrolled diabetes (with HbA1c (glycated hemoglobin) > 8%) ; - Patients who are hypothyroid and not on adequate replacement therapy ; - Patients who have congestive heart failure (NYHA (New York Heart Association) Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, advanced heart block or a history of clinically significant bradycardia or acute myocardial infarction within the 6 months preceding randomization ; - Patients with history of syncope or family history of idiopathic sudden death ; - Patients with screening or baseline (predose) : QTcF > 450 msec (male), QTcF > 460 msec (female) (QT interval corrected for heart rate using Fridericia's correction) ; - Patients with not corrected hypokalaemia and/or hypomagnesaemia ; - Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with ALT/AST (alanine transaminase/aspartate transaminase) > 2 x ULN (Upper Limit of Normal), serum bilirubin > 2 x ULN ; - Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control ; - Patients with active malignant disease within the last five years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix) ; - Patients with abnormal coagulation (PT and/or APTT elevated by 30% above normal limits) or patients receiving anticoagulants that affect PT (prothrombin time) or APTT (activated partial thromboplastin time) ; - Patients with known hypersensitivity to somatostatin analogues or any other component of the pasireotide LAR ; - Patients under guardianship ; - Patients nonaffiliated to a social insurance regime.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The decrease of enterostomy output (ml/24H) evaluated 72 hours after first injection of treatment, in both arms. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
72 hours after first injection of treatment |
|
E.5.2 | Secondary end point(s) |
- Number of patients in both arms with an enterostomy output less than 800ml/24h AND a normal renal function (Glomerular Filtration Rate> 90 ml/min according to Cockroft formula) within a week after first injection of treatment, allowing discontinuation of intravenous perfusion. - Duration of hospitalization (days), in both arms. - Rate of prematured closure of stoma due to high output (before 2 months after creation), in both arms. - Costs of taking care of patients from French Public Health Insurance perspective, in both arms (see section 11). - Nature, number and grade of adverse events observed throughout the study.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Number of patients in both arms with an enterostomy output less than 800ml/24h AND a normal renal function within a week after first injection of treatment, allowing discontinuation of intravenous perfusion.
- Rate of prematured closure of stoma due to high output (before 2 months after creation), in both arms.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 20 |
E.8.9.1 | In the Member State concerned days | |